Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031

Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031

BitgetBitget2026/10/23 13:02
  • Tempus AI expanded its collaboration with Bristol Myers Squibb under a multiyear oncology data licensing agreement running through 2031.
  • The agreement makes Bristol Myers Squibb one of its largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development.
  • Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023516440) on October 23, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Northland: The transaction between Mawell Technology and Lumentum highlights the scarce value of InP devices, benefiting related U.S. concept stocks

Northland Capital Markets has upgraded the ratings of Coherent and Applied Optoelectronics following MaxLinear's acquisition of Lumentum.

智通财经•2026/11/03 04:02

Goldman Sachs: Maintains "Buy" rating for EQT Energy (EQT.US); Mountain Resources acquisition has strategic significance

Goldman Sachs maintains a "Buy" rating on EQT Energy with a target price of $62.

智通财经•2026/11/03 03:48